FDA Authorizes Gilead's Remdesivir for COVID-19

The U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) to Gilead Sciences (NASDAQ: GILD) to use its investigational antiviral drug remdesivir to treat COVID-19. President Trump made the announcement in the Oval Office along with Gilead Chief Executive Officer Daniel O'Day, and the FDA released a letter confirming the authorization.